Two Top Researchers find Breakthrough Discoveries using Predictive Oncology’s Wholly Owned Subsidiary, TumorGenesis’s Technology
This discovery means that drugs could be targeted against that receptor site of the omentum or lining to effectively ‘block’ the metastasis of re-occurring ovarian cancer. Nearly 64% of women die from ovarian cancer in the US. The current patient population has over 21,400 new cases with nearly 13,700 dying per year, mostly from re-occurring tumors.
The second big breakthrough was done by another topflight researcher in the
By successfully growing the cell lines used for the treatment, the researchers found a defective enzyme that can be easily blocked by a class of compounds called PARGs (poly (ADP-ribose) glycohydrolase). If the enzymes are blocked, the patients treated are expected to then have a positive response to continued PARP-PARG treatment.
“Both targets of the research aided by TumorGenesis’s technology, blocking the omentum penetration and blocking the enzyme that accelerates a response to PARP treatment, once developed and approved, represent several billion dollars in future revenues for biotech or pharma companies. Three currently available PARP inhibitors, each becoming resistant to ovarian cancer over time, generate
Certain matters discussed in this release contain forward-looking statements. These forward-looking statements reflect our current expectations and projections about future events and are subject to substantial risks, uncertainties and assumptions about our operations and the investments we make. All statements, other than statements of historical facts, included in this press release regarding our strategy, future operations, future financial position, future revenue and financial performance, projected costs, prospects, plans and objectives of management are forward-looking statements. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “would,” “target” and similar expressions are intended to identify forward- looking statements, although not all forward-looking statements contain these identifying words. Our actual future performance may materially differ from that contemplated by the forward-looking statements because of a variety of factors including, among other things, factors discussed under the heading “Risk Factors” in our filings with the
Investor Relations Contact:
Source: Predictive Oncology Inc.